Avisa Diagnostics Inc, formerly FogChain Corp, is a clinical-stage medical device company. The Company develops the Avisa BreathTest, a drug/device biomarker technology platform that enables the detection of bacterial pathogens, detecting and monitoring bacterial load after the patient inhales or ingests its drug substrates. The Company conducts trials in cystic fibrosis, tuberculosis and community-acquired pneumonia. Its drug/device is in late-stage clinical development, which measures the lung and live organisms. The Company develops, AVISARTM instrument, which contains a touchscreen operator interface, nebulizer controller, breath sampling pneumatics and a laser spectrometer. Its Avisa BreathTest kit contains lyophilized AV-U13 drug, pre-filled syringe of sterile water, breath collection and biologic filter components and aerogen solo mesh nebulizer.